

Target Name	Adenosine A <sub>2A</sub> receptor
Target TTD ID	TTDS00187

Target Species	Human
Chemical Type	Adenosine analogues
Mode of Action	Agonist
QSAR Model 1	$\log(A_2K_i) = -0.50(\pm 0.31) \cdot \log k' + 0.19(\pm 0.06) \cdot (\log k')^2 + 3.05(\pm 0.34)$ $N = 8 \quad S = 0.25 \quad R^2 = 0.92 \quad F = 28.87 \quad p < 0.0018$
Molecular Descriptor	<p>Access the following web-servers to compute molecular descriptors: <a href="#">MoDel</a> and <a href="#">e-dragon</a></p> <p>Log K': lipophilicity; N is the number of compounds included in the analysis, S is the root mean square error, R<sup>2</sup> is the square of the correlation coefficient, F relates the variance of the null hypothesis to the correlation variance, p is the probability that a random set of data would yield a higher F value, and terms are given ± their standard errors.</p>
Reference	Quantitative Structure Activity Relationships as Useful Tools for the Design of New Adenosine Receptor Ligands. 1. Agonist. <i>Current Medicinal Chemistry</i> , 2006, 13, 2253-2266

Target Species	Human
Chemical Type	Adenosine analogues
Mode of Action	Agonist

<b>QSAR Model 1</b>	$\log(K_i) = 1.038 - 54.677 \cdot (R6u+) + 1.793 \cdot HGM - 23.814(R5e+) + 15.137 \cdot (HATS3u) - 14.396 \cdot (R1v+)$ <p>N = 29 S = 0.375 R<sup>2</sup> = 0.778 F = 16.149 p &lt; 10<sup>-5</sup> q<sup>2</sup><sub>LOO</sub> = 0.681 S<sub>CV-LOO</sub> = 0.464</p>
<b>QSAR Model 2</b>	$\log(K_i) = 0.001 - 0.371 \cdot {}^1\Omega R6u+ + 0.604 \cdot {}^2\Omega HGM - 0.307 \cdot {}^3\Omega R5e+ + 0.392 \cdot {}^4\Omega HATS3u - 0.280 \cdot {}^5\Omega R1v+$ <p>N = 28 S = 0.331 R<sup>2</sup> = 0.831 F = 21.658 p &lt; 10<sup>-5</sup> q<sup>2</sup><sub>LOO</sub> = 0.793 S<sub>CV-LOO</sub> = 0.362</p>
<b>QSAR Model 3</b>	$-\log(K_i) = 0.22 + 0.07 \cdot {}^1\Omega RDF075p - 0.11 \cdot {}^2\Omega RDF135m - 0.10 \cdot {}^3\Omega RDF130v + 0.18 \cdot {}^4\Omega RDF100m - 0.15 \cdot {}^5\Omega RDF140m$ <p>N = 28 S = 0.299 R<sup>2</sup> = 0.849 F = 24.812 p &lt; 10<sup>-5</sup> q<sup>2</sup>(LOO) = 0.786 S<sub>LOO</sub> = 0.368 q<sup>2</sup>(LGO) = 0.749 S<sub>LGO</sub> = 0.407</p>
<b>Molecular Descriptor</b>	<p>Access the following web-servers to compute molecular descriptors: <a href="#">MoDel</a> and <a href="#">e-dragon</a></p> <p>Topological: MSD, CIC1, VRA1, MPC09, piPC09, T(N..S)</p> <p>Galvez Topological Charges indexes: GGI2, GGI3, GGI8, GGI9, GGI10, JGI5</p> <p>Randic Molecular Profiles: DP01, SP03, SP04, SP07, SP12, SP13</p> <p>Geometrical: W3D, AGDD, DDI, ADDD, MAXDP, FDI</p> <p>WHIM: E3u, P2m, G3m, L2s, E2s, Gu</p> <p>GETAWAY: H8v, REIG, R2u+, R7u+, R5v, R1v+</p> <p>The REIG descriptor is defined as the first eigenvalue of the influence/distance matrix of the magnitude in question.</p>
<b>Reference</b>	<p>Quantitative Structure Activity Relationships as Useful Tools for the Design of New Adenosine Receptor Ligands. 1. Agonist. <i>Current Medicinal Chemistry</i>, 2006, 13, 2253-2266</p>

<b>Target Species</b>	Rat
<b>Target Location</b>	Brain

<b>Chemical Type</b>	8-substituted xanthenes
<b>Mode of Action</b>	Antagonist
<b>QSAR Model 1</b>	$pK_i (A_2) = 0.66 (\pm 0.14)\pi_8 + 0.48 (\pm 0.16)\pi_1 - 0.57 (\pm 0.25)7CH_3 + 4.34 (\pm 0.28)$ $n = 38; r = 0.71; s^2 = 0.52; F = 11.78.$
<b>QSAR Model 2</b>	$pK_i (A_2) = 0.57 (\pm 0.13) \pi_8 - 0.46 (\pm 0.17)\pi_1 - 3.42 (\pm 1.75)\sigma_{m8} + 4.37 (\pm 0.27)$ $n = 25; r = 0.81; s^2 = 0.40; F = 13.27.$
<b>QSAR Model 3</b>	$pK_i (A_2) = 0.49 (\pm 0.11)\pi_8 + 0.40 (\pm 0.14)\pi_1 - 4.88 (\pm 1.44)\sigma_{m8} + 4.42 (\pm 0.22)$ $n = 24; r = 0.87; s^2 = 0.25; F = 20.50.$
<b>QSAR Model 4</b>	$pK_i (A_2) = 0.64 (\pm 0.12)\pi_8 - 0.59 (\pm 0.22)7CH_3 + 0.48 (\pm 0.14)\pi_1 + 57.87 (\pm 19.60)S_8^N - 8.07 (\pm 4.21)$ $n = 38; r = 0.78; s^2 = 0.43; F = 13.02.$
<b>QSAR Model 5</b>	$pK_i (A_2) = 0.66 (\pm 0.11)\pi_8 - 0.47 (\pm 0.21)7CH_3 + 0.41 (\pm 0.13)\pi_1$ $+ 61.57 (\pm 17.88)S_8^N + 45.39 (\pm 16.15)q_3 + 5.90 (\pm 3.19)$ $n = 38; r = 0.83; s^2 = 0.35; F = 14.17.$
<b>Molecular Descriptor</b>	<p>Access the following web-servers to compute molecular descriptors: <a href="#">MoDel</a> and <a href="#">e-dragon</a></p> <p>A<sub>1</sub> adenosine receptor binding affinity was measured by inhibition of [3H]-N6-phenylisopropyladenosine in rat brain membranes and by inhibition of N6-R-PIA-elicited inhibition of adenylate cyclase in rat fat cell membranes.</p> <p>In our MO calculations, we routinely examined: the net atomic charges; the energies of the highest occupied and lowest unoccupied molecular orbitals, the HOMO and LUMO, respectively; the dipole moments; and the donor and acceptor superdelocalizabilities.</p> <p>1) set of <math>\pi</math>-constants for the substituents: <math>\pi_1, \pi_3, \pi_7, \pi_8</math>, which describe the hydrophobicity of the substituents at the 1-, 3-, 7- and 8-positions, respectively;</p> <p>2) the set of <math>\sigma</math>-constants for the substituent R<sup>8</sup>: <math>\sigma_m, \sigma_p, \sigma^*</math>, which describe the mesomeric and inductive effect of the R<sup>8</sup>;</p> <p>3) the molecular refractivity of the substituent R<sup>8</sup>, MR<sup>8</sup>, which describes the volume of R<sup>8</sup>;</p>

	<p>4) the set of quantum chemical indices discussed above; and</p> <p>5) the indicator variables 13DPR and 7CH, which account for the presence or absence of a certain group in a certain position. The indicator variable 13DPR has value 1 when propyl groups are attached to both N<sup>1</sup> and N<sup>3</sup> and value 0 when they are absent. The indicator variable 7CH<sub>3</sub> has value 1 when a methyl group is present at the 7-position and value 0 when a hydrogen is present. These indicator variables quantify the effect of a substituent on the biological activity that cannot be attributed to the physicochemical properties considered.</p>
<b>Reference</b>	QSAR studies of S-substituted xanthenes as adenosine receptor antagonists. <i>Eur J Med Chem</i> (1994) 29,133-138